CJC-1295 with DAC
Research Peptide
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analog modified with Drug Affinity Complex (DAC) technology to extend its duration of activity. It has been widely investigated in preclinical research for its potential effects on growth hormone signaling, tissue regeneration, recovery, and metabolic function.
Potential Research Applications
Current preclinical and investigational research has explored CJC-1295 with DAC for its potential role in:
- Supporting growth hormone research
- Promoting IGF-1 signaling
- Supporting muscle recovery
- Investigating body composition
- Supporting tissue regeneration
- Promoting protein synthesis
- Supporting metabolic function
- Investigating healthy aging pathways
Mechanism of Action
Although research is ongoing, CJC-1295 with DAC has demonstrated activity through several biological pathways, including:
- Stimulation of growth hormone-releasing hormone (GHRH) receptors
- Sustained promotion of endogenous growth hormone release
- Support of IGF-1 production and signaling
- Modulation of protein synthesis and recovery pathways
- Support of metabolic regulation in experimental models
These mechanisms have made CJC-1295 with DAC a significant area of interest in regenerative medicine and endocrine research.
Product Information
- High-purity lyophilized research peptide
- Manufactured under strict quality standards
- Third-party tested for identity and purity
- Intended exclusively for laboratory and scientific research applications
Research Disclaimer
This product is intended for laboratory research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use and is not intended to diagnose, treat, cure, or prevent any disease. It should only be handled by qualified professionals in appropriate research settings.














